The University of Hong Kong has patented new transcription antitermination protein NusB/N-utilization substance E (NusE) interaction inhibitors reported to be useful for the treatment of gram-positive or gram-negative bacterial infections and fungal infections.
Boyuan Pharmaceutical (Suzhou) Co. Ltd. has disclosed new herpes simplex virus (HSV) inhibitors potentially useful for the treatment of HSV infection and dementia.
Work at Shanghai Jeyou Pharmaceutical Co. Ltd. has led to the identification of new thioether-substituted galactopyranoside derivatives acting as galectin-3 (LGALS3) inhibitors.
Researchers from Sunshine Biopharma Inc. and the University of Arizona reported the discovery and preclinical characterization of MR-1-114, a noncovalent inhibitor of the SARS-CoV-2 papain-like protease (PLpro).
Cytoskeleton-associated protein 2 (CKAP2) is the most potent microtubule growth factor identified so far and is considered an undruggable protein, often associated with malignant progression in cancer by targeting the FAK-ERK2 signaling pathway. Using its proprietary platform, Soley Therapeutics Inc. has discovered a small molecule that modulates CKAP2 – STX-6398.
The interleukin-1 receptor accessory protein (IL1RAP) is expressed in cancer cells within the tumor microenvironment of several cancer types and plays a role in tumor development. DXP-106 is a humanized monoclonal antibody developed by Singlomics Biopharmaceuticals Co. Ltd. that binds to a unique epitope of IL1RAP domain 2 that competes with cytokines.
Researchers from Rottapharm Biotech Srl have reported preclinical efficacy data on CR-10049, a long-acting osteoarthritis-targeted multikinase inhibitor, designed to treat both osteoarthritis pain and inflammatory joint degeneration.
Researchers from McGill University and collaborating institutions aimed to investigate whether oligonucleotides are a viable drug class to prevent hydrocephalus.
RSS
